Novel Coronavirus SARS-CoV-2
i
Credit: National Institute of Allergy and Infectious Diseases-Rocky Mountain Laboratories, NIH
In response to the unprecedented threat caused by the COVID-19 outbreak, IDDO is working with key stakeholders to identify how our expertise can be used optimally. Our technical and personnel resources are mobilised to address the knowledge gaps and improve outcomes for people affected by the novel coronavirus.
COVID-19 response

The urgency of the international response to the pandemic has challenged the research community’s coordination and collaboration, resulting in hundreds of independent efforts to test and trial interventions.

IDDO is working with key stakeholders including ISARIC and with the WHO’s GOARN to mobilise optimally our resources. We support the work of both of these organisations to respond to the pandemic and accelerate better treatments for patients.

Our work on COVID-19

We are working on a living systematic review, and a searchable and interactive visualisation of the results database is being created.

We are part of a global group of scientists, physicians, funders, and policy makers from 70+ institutions in 30+ countries who have launched a Clinical Research Coalition to respond to COVID-19 in resource-poor settings.

 

Medicine Quality and COVID-19

IDDO’s Medicine Quality Research Group has developed a system for collating and curating global data on the quality of essential medical products and occurrence of substandard and falsified (SF) medical products in the lay press – the MQM Globe.

 

Wider Tools and Resources available across the COVID-19 scientific community

 

Explore our COVID-19 publications

News